Observational studyBMC pediatrics2026
NINJ1 as a novel biomarker of intestinal injury in necrotizing enterocolitis.
Observational study in BMC pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundNecrotizing enterocolitis (NEC) remains a lethal gastrointestinal emergency in neonates with an elusive etiology. Ninjurin-1 (NINJ1) mediates plasma membrane rupture during lytic cell death, yet its role in NEC remains undefined. This study investigated the clinical relevance of NINJ1 in NEC progression and evaluated its utility as a biomarker for disease severity.
methodsWe conducted a prospective observational study quantifying serum NINJ1 levels via ELISA in 68 neonates with NEC and 42 gestational age-matched controls without infection. The NEC cohort was stratified by treatment modalities and complications into surgical vs. medical management, and perforated vs. non-perforated subgroups. Immunohistochemistry (IHC) of resected specimens and bioinformatics analysis of the public GSE46619 dataset were performed to evaluate tissue-level NINJ1 expression. Diagnostic performance for surgical intervention and perforation was assessed using receiver operating characteristic (ROC) analysis.
resultsSerum NINJ1 levels were significantly elevated in neonates with NEC compared to controls (p < 0.001). Stratified analysis revealed further significant increases in infants requiring surgery (n = 28) compared to those managed medically (n = 40) (p < 0.01), and in perforated (n = 26) versus non-perforated cases (n = 42) (p < 0.01). For predicting surgical intervention, NINJ1 (AUC: 0.73) outperformed PCT (AUC: 0.65) and CRP (AUC: 0.62). At a cutoff of 131.03 pg/mL, NINJ1 yielded a specificity of 85.1% for assessing surgical risk. Notably, a combined model integrating NINJ1, CRP, and PCT further improved the AUC for predicting surgical intervention to 0.79. Furthermore, NINJ1 demonstrated the strongest single predictive capacity for bowel perforation (AUC: 0.75).
conclusionCirculating NINJ1 is significantly upregulated in severe NEC, particularly in cases complicated by perforation or requiring surgical intervention. These findings position NINJ1 as a promising biomarker for assessing the severity of intestinal injury in NEC neonates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.